Lawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused 'Stomach Paralysis'
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Aug. 3, 2023 -- A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk for severe stomach problems.
The lawsuit seeks "very significant" but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Florida.-based firm Morgan & Morgan.
Pennock filed the lawsuit Wednesday on behalf of Jaclyn Bjorklund, 44, NBC News reported. The lawsuit against Novo Nordisk and Eli Lilly claims Bjorklund was "severely injured" after taking the two diabetes drugs. Pennock said she is suffering "persistent" vomiting and severe gastroparesis.
The glucagon-like peptide 1 (GLP-1) agonists slow food's movement and have been found to cause some gastrointestinal issues in clinical trials. Those are listed as side effects on the drug labels. Both Ozempic and Mounjaro have the phrase "delays gastric emptying" on their prescribing information, though they do not specifically use the word "gastroparesis," NBC News reported.
A U.S. Food and Drug Administration spokeswoman said it was unclear whether the GLP-1 medications contribute to gastroparesis. "If newly identified safety signals are identified, the FDA will determine what actions are appropriate after a thorough review of the body of evidence," spokeswoman Chanapa Tantibanchachai said in a statement, NBC News reported.
Eli Lilly did not respond to an NBC News request for comment, and a Novo Nordisk spokeswoman said the company was unaware of the lawsuit. "Patient safety is of utmost importance to Novo Nordisk," said spokeswoman Natalia Salomao. "We recommend patients take these medications for their approved indications and under the supervision of a health care professional."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Small Differences in Weight Change With First-Line Antidepressants
MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...
American Diabetes Association, June 21-24
The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world...
Few With Type 2 Diabetes Receive Guideline-Recommended CKD Screening
MONDAY, July 1, 2024 -- Fewer than one-quarter of patients with type 2 diabetes (T2D) receive recommended chronic kidney disease (CKD) screening, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.